富含白的α-2糖蛋白1与患有外围动脉疾病的患者的死亡风险增加有关
Axel Muendlein1, Andreas Leiherer2,3,4, Eva Maria Brandtner2
1Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Carinagasse 47, 6800, Feldkirch, Austria. axel.muendlein@vivit.at.
概括
富含白的α-2糖蛋白1 (LRG1) 预测了周围动脉疾病 (PAD) 患者的10年死亡率,独立于传统的风险因素. 这种炎症标志物改善了所有原因死亡率的风险预测,与显著的性别相关差异.
科学领域:
- 心血管研究研究心血管研究
- 生物标志物发现发现
- 炎症和免疫学 炎症和免疫学
背景情况:
- 富含白的α-2糖蛋白1 (LRG1) 是一种促炎性蛋白质,与新血管化和不良临床结果有关.
- 在外周动脉疾病 (PAD) 中LRG1的预后价值仍然在很大程度上没有特征.
研究的目的:
- 研究LRG1对已确定的PAD患者临床结果的潜在预测价值.
- 评估LRG1与所有原因死亡率,心血管死亡率和主要心血管不良事件 (MACE) 在10年期间的关联.
主要方法:
- 对295名超声波确认PAD的患者进行前性研究.
- 对主要终点进行10年随访:全因死亡率,心血管死亡率和MACE.
- 单变量和多变量考克斯回归分析,包括对性别相关差异的子组分析.
主要成果:
- 在单变量分析中,LRG1显著与所有原因死亡率 (HR 3.12) 和心血管死亡率 (HR 2.58) 的风险增加有关.
- 在多变量分析中,LRG1与所有原因和心血管死亡率的关联仍然显著,独立于传统的风险因素.
- LRG1提高了传统风险模型预测所有原因死亡率的区分能力.
结论:
- LRG1是PAD患者10年死亡率的强大,独立的预测因子.
- LRG1提供了超越所有原因死亡的传统风险因素的增强预后价值.
- 对LRG1的预后价值的性别相关差异需要进一步调查.
相关概念视频
Peripheral Artery Disease I: Introduction
313
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
313
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
358
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
358
Atherosclerosis III: Management
319
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
319
Peripheral Artery Disease III: Interprofessional Care
242
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
242
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
538
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
538
Peripheral Artery Disease IV: Nursing Management
349
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
349


